Details of the Drug
General Information of Drug (ID: DMB9OGI)
Drug Name |
N-Methyl-N-Propargyl-1(R)-Aminoindan
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
124192-87-6; N-METHYL-N-PROPARGYL-1(R)-AMINOINDAN; (R)-N-Methyl-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (R)-2,3-Dihydro-N-methyl-N-2-propynyl-1H-inden-1-amine; (R)-N-Methyl-N-(2-propynyl)-2,3-dihydroinden-1-amine; UNII-1Y7XS87IZR; 1Y7XS87IZR; CHEMBL436947; (1R)-N-methyl-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; N-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YL]-N-METHYL-N-PROP-2-YNYLAMINE; R-MPAI; N-Methyl-N-2-propynyl-1-indanamine, (R)-; AC1NRD15; 1H-Inden-1-amine,2,3-dihydro-N-methyl-N-2-propyn-1-yl-, (1R)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 185.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||